{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:09:27Z","timestamp":1794964167110,"version":"4.9.1"},"reference-count":57,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,19]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>We have developed a first-in-class C-terminal HSP90 inhibitor (AX) that is effective against TKI-resistant CML and leukemic stem cells. Unlike the majority of HSP90 inhibitors, AX does not induce the HSR as a resistance mechanism.<\/jats:p>","DOI":"10.1182\/blood-2017-10-810986","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T15:54:12Z","timestamp":1525362852000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response"],"prefix":"10.1182","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6494-7744","authenticated-orcid":false,"given":"Sanil","family":"Bhatia","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7877-0262","authenticated-orcid":false,"given":"Benedikt","family":"Frieg","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"John von Neumann Institute for Computing, J\u00fclich Supercomputing Centre, Institute for Complex Systems\u2013Structural Biochemistry (ICS-6), Forschungszentrum J\u00fclich GmbH, J\u00fclich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Ahlert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stein","sequence":"additional","affiliation":[{"name":"Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertan","family":"Bopp","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, PharmaCampus, Westphalian Wilhelms University, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zang","sequence":"additional","affiliation":[{"name":"Institute for Physical Biology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J\u00fclich GmbH, J\u00fclich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Internal Medicine II, Jena University Hospital, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"K\u00f6gler","sequence":"additional","affiliation":[{"name":"Institute for Transplantation Diagnostics and Cell Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krieg","sequence":"additional","affiliation":[{"name":"Department of Surgery (A), Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"L\u00fcdeke","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana J.","family":"Rodrigues Moita","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias U.","family":"Kassack","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Marquardt","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"},{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Institute of Neuropathology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Division of Pediatric Neuro-Oncogenomics, German Cancer Consortium, partner site University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike V.","family":"Opitz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Remke","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"},{"name":"Institute of Neuropathology, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Division of Pediatric Neuro-Oncogenomics, German Cancer Consortium, partner site University Hospital D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Babor","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Grez","sequence":"additional","affiliation":[{"name":"Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Internal Medicine II, Jena University Hospital, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Groth","sequence":"additional","affiliation":[{"name":"Institute for Biochemical Plant Physiology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luitgard","family":"Nagel-Steger","sequence":"additional","affiliation":[{"name":"Institute for Physical Biology, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum J\u00fclich GmbH, J\u00fclich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Jose","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, PharmaCampus, Westphalian Wilhelms University, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-4224","authenticated-orcid":false,"given":"Thomas","family":"Kurz","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8613-1447","authenticated-orcid":false,"given":"Holger","family":"Gohlke","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"John von Neumann Institute for Computing, J\u00fclich Supercomputing Centre, Institute for Complex Systems\u2013Structural Biochemistry (ICS-6), Forschungszentrum J\u00fclich GmbH, J\u00fclich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9765-5975","authenticated-orcid":false,"given":"Finn K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany;"},{"name":"Pharmaceutical\/Medicinal Chemistry, Institute of Pharmacy, Leipzig University, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-3058","authenticated-orcid":false,"given":"Julia","family":"Hauer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111911040372800_B1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for cancer therapy","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br J Cancer"},{"key":"2019111911040372800_B2","first-page":"757694","article-title":"Hsp90 inhibitors for the treatment of chronic myeloid leukemia","volume-title":"Leuk Res Treatment","author":"Khajapeer","year":"2015"},{"issue":"6","key":"2019111911040372800_B3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.leukres.2015.03.016","article-title":"The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine","volume":"39","author":"Lazenby","year":"2015","journal-title":"Leuk Res"},{"issue":"3","key":"2019111911040372800_B4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/138161213804143725","article-title":"The therapeutic target Hsp90 and cancer hallmarks","volume":"19","author":"Miyata","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"9","key":"2019111911040372800_B5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ja.2011.60","article-title":"Molecular basis for the actions of Hsp90 inhibitors and cancer therapy","volume":"64","author":"Yamaki","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"issue":"7","key":"2019111911040372800_B6","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/leu.2008.89","article-title":"Disruption of the Bcr-Abl\/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin","volume":"22","author":"Wu","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111911040372800_B7","first-page":"933","article-title":"Geldanamycin selectively destabilizes and conformationally alters mutated p53","volume":"11","author":"Blagosklonny","year":"1995","journal-title":"Oncogene"},{"issue":"12","key":"2019111911040372800_B8","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1021\/acs.jmedchem.5b01106","article-title":"Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through Hsp90-kinase Interactions","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"issue":"4","key":"2019111911040372800_B9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2011.08960.x","article-title":"Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention","volume":"156","author":"Reikvam","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111911040372800_B10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12192-008-0035-3","article-title":"Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells","volume":"13","author":"Flandrin","year":"2008","journal-title":"Cell Stress Chaperones"},{"issue":"10","key":"2019111911040372800_B11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.celrep.2015.10.073","article-title":"A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species","volume":"13","author":"Zong","year":"2015","journal-title":"Cell Reports"},{"issue":"22","key":"2019111911040372800_B12","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2015-03-635821","article-title":"Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias","volume":"126","author":"Kucine","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111911040372800_B13","first-page":"554","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype","volume":"15","author":"Wells","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"11","key":"2019111911040372800_B14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-15-0234","article-title":"Maximizing the therapeutic potential of HSP90 inhibitors","volume":"13","author":"Butler","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"2","key":"2019111911040372800_B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4155\/fmc.14.154","article-title":"Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?","volume":"7","author":"Wang","year":"2015","journal-title":"Future Med Chem"},{"issue":"9","key":"2019111911040372800_B16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/156652412803306657","article-title":"Inhibiting HSP90 to treat cancer: a strategy in evolution","volume":"12","author":"Whitesell","year":"2012","journal-title":"Curr Mol Med"},{"issue":"17","key":"2019111911040372800_B17","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1016\/j.bmcl.2010.06.108","article-title":"Hsp90 inhibition: elimination of shock and stress","volume":"20","author":"Duerfeldt","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"2019111911040372800_B18","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/0008-5472.CAN-06-2968","article-title":"Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin","volume":"67","author":"Maloney","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"2019111911040372800_B19","first-page":"3312","article-title":"Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents","volume":"6","author":"Bagatell","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2019111911040372800_B20","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1158\/0008-5472.CAN-06-1629","article-title":"Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism","volume":"66","author":"McCollum","year":"2006","journal-title":"Cancer Res"},{"issue":"22","key":"2019111911040372800_B21","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1158\/0008-5472.CAN-05-1799","article-title":"Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin","volume":"65","author":"Guo","year":"2005","journal-title":"Cancer Res"},{"issue":"14","key":"2019111911040372800_B22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.4155\/fmc.14.89","article-title":"Alternative approaches to Hsp90 modulation for the treatment of cancer","volume":"6","author":"Hall","year":"2014","journal-title":"Future Med Chem"},{"issue":"8","key":"2019111911040372800_B23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1039\/C4CC07284G","article-title":"N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes","volume":"51","author":"Wang","year":"2015","journal-title":"Chem Commun (Camb)"},{"issue":"1","key":"2019111911040372800_B24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2407-11-468","article-title":"Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells","volume":"11","author":"Eskew","year":"2011","journal-title":"BMC Cancer"},{"issue":"5","key":"2019111911040372800_B25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cmdc.201600595","article-title":"How selective are Hsp90 inhibitors for cancer cells over normal cells?","volume":"12","author":"Wang","year":"2017","journal-title":"ChemMedChem"},{"issue":"1","key":"2019111911040372800_B26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"Suppl 3","key":"2019111911040372800_B27","first-page":"49","article-title":"Management of chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors treatment","volume":"10","author":"Wieczorek","year":"2016","journal-title":"Biomark Insights"},{"issue":"2","key":"2019111911040372800_B28","first-page":"114","article-title":"Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors","volume":"21","author":"Ursan","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"2019111911040372800_B29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2019111911040372800_B30","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111911040372800_B31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111911040372800_B32","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111911040372800_B33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bbagen.2016.01.005","article-title":"Design and biological testing of peptidic dimerization inhibitors of human Hsp90 that target the C-terminal domain","volume":"1860","author":"Bopp","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2019111911040372800_B34","doi-asserted-by":"crossref","first-page":"e96031","DOI":"10.1371\/journal.pone.0096031","article-title":"Resolving hot spots in the C-terminal dimerization domain that determine the stability of the molecular chaperone Hsp90","volume":"9","author":"Ciglia","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"2019111911040372800_B35","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/ci400370y","article-title":"Binding region of alanopine dehydrogenase predicted by unbiased molecular dynamics simulations of ligand diffusion","volume":"53","author":"Gohlke","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"9","key":"2019111911040372800_B36","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J Chem Theory Comput"},{"issue":"11","key":"2019111911040372800_B37","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2015.146","article-title":"Control of AC133\/CD133 and impact on human hematopoietic progenitor cells through nucleolin","volume":"29","author":"Bhatia","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"2019111911040372800_B38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","article-title":"A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib","volume":"94","author":"Ernst","year":"2009","journal-title":"Haematologica"},{"issue":"17","key":"2019111911040372800_B39","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood-2013-04-494773","article-title":"Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells","volume":"122","author":"Okabe","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111911040372800_B40","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070.015k17_1070_1079","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2019111911040372800_B41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.biochem.75.103004.142738","article-title":"Structure and mechanism of the Hsp90 molecular chaperone machinery","volume":"75","author":"Pearl","year":"2006","journal-title":"Annu Rev Biochem"},{"issue":"49","key":"2019111911040372800_B42","doi-asserted-by":"crossref","first-page":"17600","DOI":"10.1002\/chem.201602521","article-title":"\u03b1-Aminoxy oligopeptides: synthesis, secondary structure, and cytotoxicity of a new class of anticancer foldamers","volume":"22","author":"Diedrich","year":"2016","journal-title":"Chem Eur J"},{"issue":"2","key":"2019111911040372800_B43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"5531","key":"2019111911040372800_B44","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"5","key":"2019111911040372800_B45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/13543784.2014.902442","article-title":"Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions","volume":"23","author":"Jhaveri","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"2019111911040372800_B46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2019111911040372800_B47","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/cncr.25599","article-title":"Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27","volume":"117","author":"Hsu","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"2019111911040372800_B48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4161\/cbt.23626","article-title":"Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells","volume":"14","author":"Gandhi","year":"2013","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"2019111911040372800_B49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-013-2510-5","article-title":"A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer","volume":"139","author":"Modi","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2019111911040372800_B50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","article-title":"A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors","volume":"273","author":"Zhou","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"7","key":"2019111911040372800_B51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/ml500114p","article-title":"Chemically accessible hsp90 inhibitor that does not induce a heat shock response","volume":"5","author":"Koay","year":"2014","journal-title":"ACS Med Chem Lett"},{"issue":"18","key":"2019111911040372800_B52","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1016\/j.bmc.2010.07.042","article-title":"Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives","volume":"18","author":"Sellers","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"47","key":"2019111911040372800_B53","doi-asserted-by":"crossref","first-page":"37181","DOI":"10.1074\/jbc.M003701200","article-title":"The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone","volume":"275","author":"Marcu","year":"2000","journal-title":"J Biol Chem"},{"issue":"25","key":"2019111911040372800_B54","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/bi0497998","article-title":"Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions","volume":"43","author":"Yun","year":"2004","journal-title":"Biochemistry"},{"issue":"30","key":"2019111911040372800_B55","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.2174\/138161212802651553","article-title":"Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application","volume":"18","author":"Metz","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"7087","key":"2019111911040372800_B56","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nature04716","article-title":"Crystal structure of an Hsp90-nucleotide-p23\/Sba1 closed chaperone complex","volume":"440","author":"Ali","year":"2006","journal-title":"Nature"},{"issue":"5","key":"2019111911040372800_B57","doi-asserted-by":"crossref","first-page":"e19961","DOI":"10.1371\/journal.pone.0019961","article-title":"The hexameric structures of human heat shock protein 90","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/3\/307\/1372318\/blood810986.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/3\/307\/1372318\/blood810986.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T13:56:19Z","timestamp":1574171779000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/3\/307\/39262\/Targeting-HSP90-dimerization-via-the-C-terminus-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-10-810986","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]}}}